Hormone therapy can start before, during, or after radiation, depending on your cancer type and risk level. For prostate cancer, which is the most common scenario for this combination, hormone therapy typically begins 8 to 11 weeks before radiation starts, not after it ends. For breast cancer, endocrine therapy often begins concurrently with radiation or shortly after surgery. The exact timing depends on your specific diagnosis, risk category, and treatment plan.
Prostate Cancer: Hormone Therapy Usually Starts Before Radiation
If you’re preparing for radiation treatment for prostate cancer, the sequence may be the opposite of what you’d expect. In most cases, hormone therapy (called androgen deprivation therapy, or ADT) begins weeks before your first radiation session, not after your last one. The goal is to shrink the tumor before radiation, making the radiation more effective at killing remaining cancer cells.
A large study using the National Cancer Database, covering over 37,000 patients treated between 2004 and 2015, found that starting hormone therapy 8 to 11 weeks before radiation produced the best survival outcomes. Patients in that window had a 10% lower risk of death compared to those who started hormone therapy less than 8 weeks before radiation. Interestingly, starting more than 11 weeks early didn’t provide additional benefit, suggesting there’s a sweet spot.
The 2025 NCCN guidelines reflect this approach. For unfavorable intermediate-risk prostate cancer, hormone therapy lasts 4 to 6 months total, preferably given during and after radiation. For high-risk or very-high-risk prostate cancer, hormone therapy is given before, during, and after radiation for a total of 18 months to 3 years. So “after radiation” is really just one phase of a longer course that brackets the radiation on both sides.
How Long Hormone Therapy Continues After Radiation
The duration of hormone therapy after your last radiation session depends on your risk group:
- Unfavorable intermediate risk: A total course of 4 to 6 months of ADT, with most of it given during and after radiation.
- High risk or very high risk: A total course of 18 months to 3 years, meaning you’ll continue hormone therapy for well over a year after radiation ends. If you’re receiving both external beam radiation and brachytherapy (internal seed implants), a shorter course of about 1 year may be possible.
- Very high risk with additional targeted therapy: Hormone therapy for roughly 2 years, combined with a daily oral medication that blocks additional hormone production pathways.
For brachytherapy specifically, the typical pattern is 3 months of hormone therapy before the seed implant and 3 months after, for a total of 6 months. External beam radiation then follows 4 to 8 weeks after brachytherapy.
What Hormone Therapy Looks Like in Practice
Hormone therapy for prostate cancer isn’t a single pill or shot. It usually involves a combination of treatments. The core treatment is a medication that dramatically lowers testosterone, delivered as an injection or small implant under the skin. These shots are given on schedules ranging from once a month to once a year, depending on the specific drug. Some patients also take a daily pill that blocks testosterone from binding to cancer cells, a combination known as combined androgen blockade.
You won’t need to visit a radiation center for hormone therapy. The injections are typically given at your oncologist’s or urologist’s office, and pills are taken at home. This means the transition from active radiation treatment to ongoing hormone therapy feels like a significant shift in routine: fewer clinic visits, but a new set of side effects to manage.
Overlapping Side Effects to Expect
One practical concern about starting or continuing hormone therapy around the same time as radiation is the overlap in side effects. Radiation commonly causes fatigue that can persist for weeks after treatment ends. Hormone therapy brings its own fatigue, along with hot flashes, weight gain, reduced sexual desire, mood changes, and loss of bone density over time. When these overlap, the cumulative tiredness can be significant.
The side effects of hormone therapy tend to increase the longer you’re on it. This is one reason researchers have explored whether some patients can safely shorten their course. For men whose cancer recurs after initial radiation, some centers have investigated using targeted procedures like cryoablation to delay the start of hormone therapy by two or more years, specifically to avoid prolonged exposure to ADT’s side effects, which include increased risk of heart disease and osteoporosis.
Breast Cancer: A Different Timeline
If your search is about breast cancer rather than prostate cancer, the timing works differently. Endocrine therapy (such as tamoxifen or aromatase inhibitors) is often started concurrently with radiation rather than sequenced before or after it. In several large international trials, most patients began endocrine therapy within two days of being assigned to treatment, and radiation was delivered at the same time.
The key concern with breast cancer treatment sequencing is avoiding long delays in starting any adjuvant therapy after surgery. Research on related targeted therapies has shown that delays beyond 42 days after surgery are associated with meaningfully worse outcomes: one study found that patients who started treatment after that window had a 2.5 times higher risk of recurrence and a 4.5 times higher risk of death. While these numbers come from a study on a targeted therapy rather than standard endocrine therapy, they illustrate why oncologists generally aim to start post-surgical treatments promptly.
Why Timing Varies Between Patients
Your oncologist may adjust the standard timeline for several reasons. If you’re recovering from surgery, your body may need time to heal before adding hormone therapy. If radiation caused significant skin irritation or fatigue in the treatment area, your team might give you a brief window to recover. Existing heart conditions or bone density concerns can also influence how quickly hormone therapy begins, since these are areas where ADT carries long-term risks.
The most important factor is your cancer’s risk level. Lower-risk cancers may need shorter courses or no hormone therapy at all. Higher-risk cancers benefit from longer, more aggressive hormone suppression that starts early and continues well after radiation is complete. If you’re unsure which category you fall into, your treatment summary or pathology report will list your risk group, and your care team can explain how that translates to a specific hormone therapy schedule.